These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 25987336)
21. Immunotherapy of metastatic renal cell cancer. Fishman M; Seigne J Cancer Control; 2002; 9(4):293-304. PubMed ID: 12228755 [TBL] [Abstract][Full Text] [Related]
22. [Chances for the success of cytokine therapy in metastatic renal cell cancer]. Kriegmair M Fortschr Med; 1992 Aug; 110(24):435-6. PubMed ID: 1398389 [No Abstract] [Full Text] [Related]
23. Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. Linehan WM; Walther MM; Alexander RB; Rosenberg SA Semin Urol; 1993 Feb; 11(1):41-3. PubMed ID: 8465127 [No Abstract] [Full Text] [Related]
28. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
29. [The role of immunotherapy in metastatic cancer of the kidney]. Thiounn N J Urol (Paris); 1994; 100(5):231-7. PubMed ID: 7730669 [TBL] [Abstract][Full Text] [Related]
30. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience. Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623 [TBL] [Abstract][Full Text] [Related]
31. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Figlin RA; Pierce WC; Belldegrun A Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686 [No Abstract] [Full Text] [Related]
32. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials]. Doehn C; Jocham D Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376 [TBL] [Abstract][Full Text] [Related]
34. Metastatic renal-cell carcinoma: what causes occasional dramatic regressions? Young RC N Engl J Med; 1998 Apr; 338(18):1305-6. PubMed ID: 9562587 [No Abstract] [Full Text] [Related]
35. Renal cell cancer: is there long-term survival advantage from cytokine treatment? Oliver RT Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400 [No Abstract] [Full Text] [Related]
36. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Verra N; Jansen R; Groenewegen G; Mallo H; Kersten MJ; Bex A; Vyth-Dreese FA; Sein J; van de Kasteele W; Nooijen WJ; de Waal M; Horenblas S; de Gast GC Br J Cancer; 2003 May; 88(9):1346-51. PubMed ID: 12778059 [TBL] [Abstract][Full Text] [Related]
37. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma. Mickisch GH Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369 [TBL] [Abstract][Full Text] [Related]
38. Immunotherapy in metastatic renal cell carcinoma. Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434 [TBL] [Abstract][Full Text] [Related]
39. Current treatment of renal cell carcinoma. De Mulder PH; van Herpen CM; Mulders PA Ann Oncol; 2004; 15 Suppl 4():iv319-28. PubMed ID: 15477330 [No Abstract] [Full Text] [Related]
40. The current use of interferons, interleukin-2 and tumor necrosis factor in renal cell cancer. Wirth M Urol Int; 1991; 47(4):219-30. PubMed ID: 1723554 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]